Proof of concept gene therapy for TSC has been evaluated in mouse models of TSC using an adeno-associated virus (AAV) vector carrying the complement for either a full-length TSC1 or a functional engineered human TSC2, respectively (Prabhakar et al., 2019; Cheah et al., 2021). This evidence concerns the gene TSC1 and tuberous sclerosis.